The Development of Novel Anti-folates: An Ongoing Battle Against Resistance by Tran, Nhi
University of Connecticut
OpenCommons@UConn
Honors Scholar Theses Honors Scholar Program
Spring 5-1-2014
The Development of Novel Anti-folates: An
Ongoing Battle Against Resistance
Nhi Tran
University of Connecticut - Storrs, nhi.tran@uconn.edu
Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses
Recommended Citation
Tran, Nhi, "The Development of Novel Anti-folates: An Ongoing Battle Against Resistance" (2014). Honors Scholar Theses. 375.
https://opencommons.uconn.edu/srhonors_theses/375
  
 
 
 
 
 
The Development of Novel Anti-folates: An 
Ongoing Battle Against Resistance 
 
Honors Scholar Thesis 
May 2014 
 
 
 
 
 
 
 
 
Nhi N. Tran 
PharmD Candidate 2014 
University of Connecticut 
 
 
 
 
 
Research Advisor: Amy Anderson, PhD 
Department of Pharmaceutical Sciences 
University of Connecticut School of Pharmacy 
 
 
Tran 2 
 
 
Table of Contents 
 
Abstract …………………………………………………………………………………………..3 
Introduction……………………………………………………………………………………4-7 
Methods…………………………………………………………………………………….…8-10 
Results………………………………………………………………………………………..10-15 
Discussion...………………………………………………………………………………….15-16 
 
Table 1: Comparing Trimethoprim and UCP111E……………………………………………6 
Table 2: IC50 Values for DHFR…….…………………………………………………………...7 
 
Appendix A…………………………………………………………………………………17-25 
 
References…...…………………………………………………………………………………..26
Tran 3 
 
 
Abstract 
 The development of drug compounds begins with the identification of a well-validated 
target. Conserved in bacterial, fungal, and mammalian species, the folate biosynthetic pathway 
performs critical processes to promote nucleic acid synthesis and maintain cellular function. 
Medicinal chemists have particularly targeted dihydrofolate reductase (DHFR), an essential 
enzyme in this metabolic process, for several years. In fact, anti-folates that act on this pathway 
have potential roles against infectious diseases. This project examines a para-substituted drug 
compound called UCP111E, which is directed against dangerous fungal species, like Candida 
albicans and Candida glabrata. Since crystal structures of C. albicans DHFR (CaDHFR) and C. 
glabrata DHFR (CgDHFR) with UCP111E have already been solved, the main objective is to 
now deduce the structure of human DHFR (huDHFR) complexed with the drug compound. 
 Sample preparation procedures in this project used Qiagen EasyXtal 15-well trays to 
plate various conditions for crystallization. The buffer (i.e., Tris), salt (i.e., lithium sulfate), 
precipitant (i.e., PEG 4000), and additive (i.e., ethanol) remained constant for each well in the 
trays. However, non-volatile additives (i.e., 1,8-diaminooctane, strontium chloride, and calcium 
chloride) varied, with the initial focus being on 1,8-diaminooctane. 
 Several steps to improve the conditions with 1,8-diaminooctane produced plate-like 
crystals, while strontium chloride formed hexagon-shaped crystals, and calcium chloride, crystal 
rods. Only those crystals formed from 1,8-diaminooctane and calcium chloride were large 
enough to diffract. However, diffraction patterns revealed the presence of salt, rather than 
protein, in the structures. Future projects hope to continue optimizing conditions with strontium 
chloride and calcium chloride to crystallize the huDHFR/UCP111E complex. 
Tran 4 
 
 
Introduction 
Infectious disease was the primary cause of death worldwide in the early 1900s (1). 
However, Alexander Fleming’s accidental discovery of penicillin in 1928 triggered an enormous 
surge of antibiotic development in the 1930s. The first half of the twentieth century witnessed the 
advent of many antibacterial agents. Over the next thirty years, 14 different classes of antibiotics 
including beta-lactams, sulfonamides, aminoglycosides, tetracyclines, macrolides, and 
lincosamides, became available. After 1968 though, drug discovery drastically diminished, with 
the introduction of only about five more antibiotic classes (2). Equipped with these drugs, many 
assumed victory and thus, an end to the battle against infectious microorganisms. Unfortunately, 
bacteria have continually found new ways to fight back by undergoing mutations to subtly 
modify target enzymes, thereby conferring resistance. Other mechanisms of resistance, 
particularly in Gram-negative organisms, include the loss of porins, overexpression of efflux 
pumps, and creation of bypass targets, all of which help bacteria evade their imminent demise 
(1). Keeping pace with resistance mechanisms by creating new drug compounds is the only way 
to fight the ongoing war against the microbial world. 
Antimicrobial resistance remains one of the greatest threats to human health across the 
globe. Formidable drug-resistant strains, including methicillin-resistant Staphylococcus aureus 
(MRSA), vancomycin-resistant enterococcus (VRE), Pseudomonas aeruginosa, extended-
spectrum beta lactamase (ESBL) Gram-negative organisms, and Klebsiella pneumoniae 
carbapenemases (KPC), have resulted in significant morbidity and mortality. Nearly two million 
Americans annually develop hospital-acquired infections (HAI), like sepsis and pneumonia, 
which result in 99,000 deaths and cost the U.S. health care system billions of dollars. Over-
prescription and inappropriate use of antibiotics also contribute to this worldwide dilemma by 
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making the medications less effective. In addition to the unnecessary and excessive antimicrobial 
use, people may also receive the wrong drug at incorrect doses or schedules (3). The current 
development of new medications exceedingly lags behind bacteria’s natural ability to evolve and 
confer resistance. Therefore, the search for new antibiotics ultimately becomes more pressing. 
Similarly, the incidence of opportunistic fungal infections (i.e., invasive candidiasis) has 
significantly increased over the past few decades and ranks as the fourth most common cause of 
hospital-acquired bloodstream infections in the United States (4). Immunocompromised 
individuals particularly suffer from excessive morbidity and mortality after contracting 
candidemia. Other high-risk patient populations include the elderly, premature babies, solid-
organ transplant recipients, bone marrow transplant patients, and those undergoing major 
surgical procedures. Candida albicans and Candida glabrata remain two of the worst contenders 
in fungal infections. In fact, the incidence of candidiasis from C. glabrata has increased since 
1993 (5). This strain even demonstrates resistance to amphotericin B and many azole 
compounds, thereby limiting the usefulness of current antifungal compounds.  
The approval of novel antifungals appears almost as stagnant as that of antibacterial 
drugs. Amphotericin B, one of the earliest antifungal agents from the early 1950s, has activity 
against most fungi, but its infusion-related and renal toxicities somewhat limit its use. Other 
antifungals include flucytosine and griseofulvin from the early 1960s, azole compounds (i.e., 
ketoconazole, fluconazole, itraconazole, etc.) from the 1970s-80s, and caspofungin from the 
early 2000s. With very few antifungal drug classes available, the discovery of new molecular 
targets remains imperative to expand the currently limited repertoire (6).  
Dihydrofolate reductase (DHFR), an essential enzyme in the folate biosynthetic pathway, 
has been a well-validated target not only for antibacterial therapeutics, but also for anticancer 
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and antiprotozoal agents, for over 60 years (7). In the folate pathway, DHFR uses NADPH as an 
electron donor to reduce dihydrofolate to tetrahydrofolate, leading to the synthesis of essential 
purines and amino acids. Consequently, blocking DHFR with anti-proliferative drug compounds 
leads to a deficiency in tetrahydrofolate and reduces cellular growth.
 
Examples of such 
compounds include methotrexate, an anticancer agent, pyrimethamine, an antimalarial drug, and 
trimethoprim (Table 1 below), an antibacterial. Trimethoprim inhibits Gram-positive and Gram-
negative organisms (i.e., S. aureus, S. pyrogenes, S. pneumoniae, E. faecalis, E. Coli, K. 
pneumonia, and H. influenza) in vitro. Since both mammalian and bacterial cells contain DHFR, 
drug compounds need both potency and selectivity. Trimethoprim fortunately has an IC50 value 
approximately 3000 times higher for human versus bacterial DHFR, allowing for more focused 
activity in infectious diseases (7). For urinary tract infections, trimethoprim has also been used in 
combination with sulfamethoxazole to block dihydropteroate synthetase, another folate pathway 
enzyme. Unfortunately, resistant bypass enzymes and point mutations have created resistance. 
Table 1: Comparing Trimethoprim and UCP111E 
 
 
a. Trimethoprim b. UCP111E 
 
Bacterial resistance signals a need for additional structure-based drug design to 
synthesize novel anti-folates. Medicinal chemists have used trimethoprim (MW 290.32 g/mol) as 
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their base and began constructing propargyl-linked anti-folates to target DHFR. Trimethoprim’s 
structure contains a di-substituted pyrimidine ring, methylene linker, and a phenyl ring with three 
methoxy groups. Further modifications began with the synthesis of compounds containing 
biphenyl groups attached to a propargyl linker. Chemists knew that the pyrimidine helped lock 
the compound in the DHFR active site, while the propargyl linker forced the hydrophobic 
biphenyl deeper into a hydrophobic pocket. They also experimented with the biphenyl to 
optimize hydrophobic interactions and binding. Specifically, para-substituted compounds 
potently inhibited CaDHFR and CgDHFR. In this project, UCP111E (MW 388.46 g/mol), one of 
the para-substituted compounds, is examined against huDHFR. This compound contains a 
pyrimidine ring system with two amino groups, a propargyl bridge, a benzene ring with two 
methoxy substitutions, and a para-substituted phenyl ring. As seen in Table 1 below, UCP111E 
has a higher IC50 value against huDHFR compared to CaDHFR and CgDHFR. Currently, the 
goal is to examine the binding properties of UCP111E with huDHFR to further increase 
selectivity and affinity for fungal DHFR. The two methoxy groups in the biphenyl system are of 
particular interest in UCP111E. Other compounds, like UCP111F, have very similar structures to 
UCP111E, with the only difference being a missing methoxy group from the aromatic ring. 
Many of the IC50 values for UCP111F were significantly higher than that of UCP111E, 
demonstrating less potent activity. The potency for huDHFR differed, but activity against 
CaDHFR and CgDHFR was similar. 
Table 2: IC50 Values for DHFR 
Drug Compound IC50 for CaDHFR  IC50 for CgDHFR IC50 for huDHFR 
UCP111E 36 nM 8.2 nM 314 nM 
UCP111F 55 nM 9.1 nM 1.42 uM 
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Materials and Methods 
Protein Purification  
BL21 DE3 E. coli competent cells were transformed with the huDHFR gene in the 
pET41a(+) plasmid. One-liter cultures of huDHFRpET41/BL21(DE3) were grown in LB media 
containing 50 µg/mL kanamycin at 37ºC. Once the cultures reached optical densities of 0.7 to 0.9 
at 600 nm, a final concentration of 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
added to each culture. Protein expression proceeded for 6 hours at 30ºC. The cells were then 
harvested by centrifugation and subsequently stored at -80°C.  
One-liter cultures of huDHFRpET41/BL21(DE3) were dissolved in 1 x Bugbuster with 
DNase and 1mM PMSF. After incubation at room temperature, soluble lysate was collected via 
centrifugation. To remove contaminant proteins prior to chromatography, the soluble lysate was 
incubated in 60% saturation ammonium sulfate overnight at 4°C. The soluble crude protein 
sample was then added to a methotrexate column pre-equilibrated with Equilibration buffer (20 
mM Tris, 15% (v/v) glycerol, 50 mM KCl, 2mM DTT, 0.1 mM EDTA, and 1mM PMSF). 
Contaminant proteins that did not bind methotrexate were washed from the column with Wash 
buffer (20 mM Tris, 15% (v/v) glycerol, 0.5 M KCl, 2mM DTT, 0.1 mM EDTA, and 1 mM 
PMSF). The column was subsequently re-equilibrated with Equilibration buffer. HuDHFR bound 
to methotrexate beads were eluted from the column with Elution buffer (20 mM Tris, 15% (v/v) 
glycerol, 50 mM KCl, 0.1 mM EDTA, 2mM DTT, and 1mM PMSF), and the column was 
washed with more Equilibration buffer. The fractions from the methotrexate column were 
evaluated using SDS-PAGE. Fractions containing huDHFR in excess of contaminants were 
pooled and concentrated for addition to an S200 column.  
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 After further purification with the S200 column, protein was diluted with Desalting 
buffer to 8 mg/mL and flash frozen in liquid nitrogen. 
Sample Preparation and Protein Crystallization. Crystals of huDHFR bound to 
UCP111E were grown using the hanging drop method on Qiagen EasyXtal 15-well trays. 
Various conditions were plated to determine the most optimal settings for crystal formation. The 
500 μL of reservoir solution in each well contained the same basic components: Tris buffer, PEG 
4000, lithium sulfate, and ethanol. The reservoir solution was prepared, allowed to mix, and 
stored at 4°C until the sample preparation. 
For each plate, 4 μL each of 50mM NADPH and 50mM UCP111E stock (or 7.76 μL of 
10 mg/mL UCP111E stock) were added to 200 µL aliquots of huDHFR (8 mg/mL) The solution 
was left to incubate on ice for 2 hours. Afterward, the contents of the tubes were filtered, 
centrifuged, and brought to the desired final protein concentration with Desalting buffer. 
The prepared EasyXtal trays, along with Eppendorf tubes of the non-volatile additive and 
huDHFR, were placed on ice. Two microliters of reservoir solution, followed by 2 μL of 
huDHFR, were pipetted into each of the 3 cavities in the DropGuard Crystallization Support. 
Half a microliter of the corresponding concentrations of non-volatile additive was then added to 
each cavity, and the Crystallization Support was fastened to the well. After completion, the 
crystal tray was returned to 4°C for incubation. 
Freezing Crystals. The wells that produced the most promising crystals were identified, 
and 1000 μL of cryoprotectant solution were made for each condition. Each cryoprotectant 
solution contained 500 μL of the respective reservoir solution, along with 150 μL ethylene glycol 
and 350 μL diH2O. After the solutions were made, they were allowed to mix for a few hours 
before being stored at 4°C. 
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At 4 °C, crystals were harvested with Hampton Crystal Cap
TM
 Copper Magnetic HT 0.2-
0.3 mm CryoLoops, deposited into the corresponding cryoprotectant solution, and then flash 
frozen in liquid nitrogen. The CryoLoops were put in vials and assembled on a crane for storage 
in liquid nitrogen until ready to diffract in the X-ray Crystallography Facility. 
 
Results 
The main research objectives were to improve anti-folate selectivity by exploring and 
comparing the unique binding properties of anti-folates against Candida and mammalian DHFR. 
In the fight against infectious diseases, information from crystal structures of huDHFR, 
CaDHFR, and CgDHFR can direct the future design of more potent and selective drug 
compounds. The anti-folates initially developed had used data gathered from crystal structures of 
CaDHFR and CgDHFR. However, the structure of huDHFR bound to these drug compounds 
was previously difficult to attain. Although UCP111E, the compound of interest in this project, 
demonstrated lower IC50 values (and therefore, greater selectivity) for the fungal species versus 
human, chemists still aimed for a redesign to further increase the differences between the indices. 
Therefore, solving structures of huDHFR bound to propargyl-linked anti-folates was a key step 
to attaining this goal. Greater selectivity of these drug compounds would not only increase the 
efficacy against fungal infections, but would also reduce toxicity in the human host.  
The protein purification process involved affinity chromatography with a methotrexate 
column to isolate huDHFR. The lysed cell sample was added to the column, allowing for the 
binding of huDHFR to the beads containing methotrexate, a drug that impairs the formation of 
active tetrahydrofolate (THF) from inactive dihydrofolate (DHF) in the folate pathway. To elute 
huDHFR from the beads, DHF was added to the column, allowing the enzyme to preferentially 
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bind to DHF and to detach from methotrexate. Fractions containing huDHFR were confirmed 
through SDS-PAGE and gel electrophoresis. Purification of huDHFR resulting in 10 mg/L 
cultures yielded > 95% purity. 
The first crystal tray (Figure 1 in Appendix A) contained very broad conditions to 
determine the most appropriate environment for crystal formation. Concentrations of lithium 
sulfate were 0.1 M, 0.15 M, and 0.2 M in rows A, B, and C respectively. PEG 4000 was at 20% 
(v/v), 25% (v/v), 30% (v/v), 35% (v/v), and 37% (v/v) in columns 1-5. In addition, 0.1 M Tris 
and 5% (v/v) ethanol remained constant in all wells. A protein concentration of 15 mg/mL was 
used, and the non-volatile additives were 1%, 3%, and 5% 1,8-diaminooctane in cavities I, II, 
and III, respectively. When comparing the three concentrations, nothing formed in 1% 1,8-
diaminooctane, while 3% demonstrated phase separation and texture changes (seen as beige 
“oily” masses) and 5% revealed precipitation. Row B with 0.15 M lithium sulfate and column 3 
with 30% (v/v) PEG 4000 showed the most phase separation, nucleation, and early signs of 
crystal formation; whereas, row A displayed more beige-colored masses of precipitate. 
The second crystal tray (Figure 2 in Appendix A) used higher concentrations of 1,8-
diaminooctane (i.e., 3%, 5%, and 7%), but the protein concentration remained 15 mg/mL. 
Lithium sulfate concentrations were changed to 0.1 M, 0.125 M, and 0.15 M; whereas, PEG 
4000 concentrations of 18% (v/v), 20% (v/v), 22.5% (v/v), 25% (v/v), and 30% (v/v) were 
evaluated. Cavities I and II with 3% and 5% 1,8-diaminooctane, respectively, either showed no 
changes or demonstrated light to heavy precipitation with “oily” masses. This effect appeared 
most prominent in the first 3 columns with 18% (v/v), 20% (v/v) and 22.5% (v/v) PEG 4000, as 
well as in row A with 0.1 M lithium sulfate and row C with 0.15 M lithium sulfate.  Cavity III 
with 7% 1,8-diaminooctane exhibited some crystal formation seen as thin “ice-like” plates in 
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columns 4 and 5 containing 25% and 30% (v/v) PEG 4000, respectively. Rows A, B, and C also 
displayed this result. In particular, B4 with 0.125 M lithium sulfate and 25% (v/v) PEG 4000 
produced thin plates in cavities II and III. 
Protein concentration was increased to 18 and 20 mg/mL in the third EasyXtal crystal 
tray (Figure 3 in Appendix A), as were concentrations of 1,8-diaminooctane to 5%, 7%, and 
10%. PEG 4000 concentrations were carried over from the previous crystal tray, but lithium 
sulfate concentrations were changed to 0.125 M, 0.15 M, and 0.175 M. Crystal plate formation 
generally appeared in cavity III and rows A-C, with more prominent results in columns 4 and 5, 
similar to the previous tray. On the other hand, precipitation seen as small dark dots 
predominated cavity I with 5% 1,8-diaminooctane, especially in row A. 
Further plans to optimize conditions included increasing 1,8-diaminooctane 
concentrations to 7%, 10%, and 13% in the fourth plate (Figure 4 in Appendix A) and to 10%, 
15%, 20% in the fifth (Figure 5 in Appendix A). PEG 4000 at 25% (v/v), 27.5% (v/v), 30% 
(v/v), 32.5% (v/v), and 35% (v/v) were utilized in both trays. However, crystal tray #5 used 10% 
(v/v) ethanol, instead of 5% (v/v), and also required a stock of 2 M Tris buffer, rather than 1M, 
to accommodate the 500 μL volume limit for each well. Lithium sulfate concentrations between 
the third and fourth trays stayed the same, but this was increased to 0.2 M, 0.225 M, and 0.25 M 
for the fourth. Protein concentrations were 15 mg/mL. 
Upon initial examination, cavity II with 10% 1,8-diaminooctane from crystal tray #4 
consistently showed a mixture of precipitation and crystal formation seen as plates or striated 
rods in rows A-C. Cavity I containing 7% 1,8-diaminooctane also exhibited some crystals, but 
less so than in cavity II; whereas, cavity III with 13% 1,8-diaminooctane mostly revealed 
precipitation. A few weeks later though, single large plates appeared in B5, which previously had 
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no formations or just light precipitate. On the fifth tray, nearly all 3 cavities had crystal growth in 
the form of plates and needles, especially with the higher 1,8-diaminooctane concentrations. 
“Oily” formations were also mixed in with the crystals, particularly in columns 4 and 5 with 
32.5% and 35% (v/v) PEG 4000, respectively. 
In the sixth crystal tray (figure 6 in Appendix A), only lithium sulfate and PEG 4000 
concentrations were changed in the reservoir solution. Rows A, B, and C had 0.25 M, 0.3 M, and 
0.35 M lithium sulfate, respectively. Columns 1-5 had 25%, 27%, 29%, 31%, and 33% (v/v) 
PEG 4000. In addition, 10%, 15%, and 20% 1,8-diaminooctane were used. The concentration of 
huDHFR was 15 mg/mL. Row A mostly exhibited heavy, brown precipitation; however, rows B 
and C created noticeable crystals in all 3 cavities that were considered worthy of diffraction 
experiments. Crystals were gathered and flash-frozen in liquid nitrogen from C3 (0.1 M Tris, 
0.35 M lithium sulfate, 29% (v/v) PEG 400, 10% (v/v) ethanol), C4 (0.1 M Tris, 0.35 M lithium 
sulfate, 31% (v/v) PEG 4000, 10% (v/v) ethanol), and C5 (0.1 M Tris, 0.35 M lithium sulfate, 
33% (v/v) PEG 4000, 10% (v/v) ethanol).  
Crystal tray #7 (figure 7 in Appendix A) used strontium chloride as the non-volatile 
additive in concentrations of 0.075 M, 0.1 M, and 0.125 M in cavities I, II, and III, respectively. 
Tris at 0.1 M and ethanol at 8% (v/v) remained constant in all wells. Lithium sulfate varied (0.33 
M, 0.35 M, and 0.37 M) in the rows (A-C); PEG 4000 was 24% (v/v), 26.5 % (v/v), 29% (v/v), 
31.5% (v/v), and 34% (v/v) in respective columns (1-5). Protein concentration was increased to 
20 mg/mL. While all 3 rows formed tiny crystal, denser arrays of larger crystals appeared at 
higher PEG 4000 concentrations in columns 4 and 5 at 31.5% (v/v) and 34% (v/v), respectively. 
Higher concentrations of strontium chloride at 0.1 M and 0.125 M also created slightly larger 
crystals, particularly in rows A and B with 0.33 M and 0.35 M lithium sulfate, respectively. In 
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well B4 (0.1 M Tris, 0.35 M lithium sulfate, 31.5% (v/v) PEG 4000, 8.0% (v/v) ethanol), a 
hexagon-shaped crystal also appeared when the protein was exposed to 0.075 M strontium 
chloride. A foreign piece of fiber in the well may have also contributed to this phenomenon. In 
row C with 0.37 M lithium sulfate, 0.125 M strontium chloride produced larger crystals, but they 
were still too small for diffraction. Higher PEG concentrations in row C also revealed tannish-
colored masses of precipitation. 
Experimentation with different non-volatile additives continued into crystal tray #8 
(figure 8 in Appendix A), which tested the effects of calcium chloride. Tris at 0.1 M and lithium 
sulfate at 0.35 M were kept constant in all wells. PEG 4000 as 24% (v/v), 26.5% (v/v), 29% 
(v/v), 31.5% (v/v), and 34% (v/v) were in columns 1-5; whereas, ethanol was 6% (v/v), 7% (v/v), 
and 8% (v/v) in rows A-C. HuDHFR concentrations of 11 mg/mL and 15 mg/mL were used, so 
cavity I contained 0.1 M calcium chloride with 11 mg/mL protein, cavity II had 0.1 M calcium 
chloride with 15 mg/mL protein, and cavity III, 0.15 M calcium chloride and 15 mg/mL protein. 
Crystals formed within three days; however, clumps of fused crystals, rather than individual 
ones, were mostly observed in each row. The crystallization process may have occurred too 
quickly, leading to crystal conglomerations in several wells, including C1 (0.1 M Tris, 0.35 M 
lithium sulfate, 24% (v/v) PEG 4000, 8% (v/v) ethanol). Nonetheless, some wells formed single, 
large rod-shaped crystals that were considered for diffraction (i.e., A4, B2, and B5). 
The ninth plate (figure 9 in Appendix A) optimized the conditions from plate #7, with 
strontium chloride as the non-volatile additive. Rows contained 0.3 M, 0.35 M, and 0.37 M 
lithium sulfate, while PEG 4000 concentrations were broadened to 22% (v/v), 25% (v/v), 28% 
(v/v), 31.5% (v/v), and 34% (v/v) in the columns. Concentrations of huDHFR were 11 mg/mL 
and 15 mg/mL. Contents of individual cavities were as follows: 0.075 M strontium chloride and 
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11 mg/mL protein in I, 0.075 M strontium chloride and 15 mg/mL protein in II, and 0.125 M 
strontium chloride and 15 mg/mL protein in III. Heavy precipitation predominated in many 
wells, particularly those in row A. Although crystals did form, like in C1 (0.1 M Tris, 0.37 M 
lithium sulfate, 22% (v/v) PEG 4000, 8% (v/v) ethanol), precipitation was also present. The 
crystal sizes also did not differ from that in the seventh tray. 
Consult Appendix A for images of specific cavities and wells for each crystal plate. 
 
Discussion 
 For protein crystallization, adjustable parameters include the precipitant or additive 
concentration, pH, and temperature. As observed from the 1,8-diaminooctane plates in this 
project, higher concentrations of PEG 4000 and lithium sulfate in the reservoir solution generally 
had more successful crystal formations. Ethanol at 8 % (v/v) also seemed to work best, which is 
supported by previous experiments with huDHFR from K. Lamb. 
 The additive, 1,8-diaminooctane, produced crystals fairly quickly in about 1-2 weeks; 
however, the crystals were often very thin and fragile plates. Needles would form occasionally, 
but even those were difficult to harvest and freeze. As a result, other non-volatile additives were 
tested. Information from optimizing conditions in the 1,8-diaminooctane crystal trays (#1-6) 
were used to design additional trays. Known to produce more durable crystals, strontium 
chloride was plated for trays #7 and #9. The only caveat is that this additive takes about 4 weeks 
to produce results. The use of calcium chloride as different additive for tray #8 resulted in even 
more rapid crystal formation in a matter of days. Although certain conditions with calcium 
chloride created a few individual rods to form, several tended to fuse into larger clumps. 
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The aim of refining the crystallization conditions was to produce crystals of 
huDHFR/UCP111E suitable for diffraction studies. Despite the small, thin plate-like crystals 
initially seen in the 1,8-diaminooctane trays, a few larger ones (i.e., in B5 of tray #6) were seen 
after several more weeks flash-frozen in liquid nitrogen for diffraction. Hexagon-shaped crystals 
were also spotted in A5 and B1 of tray #7 with strontium chloride, but unfortunately, these were 
still too small. On the other hand, a sizable rod-shaped crystal was successfully collected for 
diffraction from B3 in tray #8 with calcium chloride. Attempts to shoot these potential crystals 
from 1,8-diaminooctane and calcium chloride in the X-ray crystallography facility yielded 
inadequate results. Based on the sparse and irregular diffraction patterns generated, these crystals 
likely contained salt, rather than protein.  
In future experiments, 1,8-diaminooctane may be abandoned as a non-volatile additive, 
due to the fragility of the resultant crystals. Several attempts were already made to optimize 
conditions with this additive, so it may be best to experiment with others in subsequent trays. 
Given the structural similarities among the crystals developed from 1,8-diaminooctane, it could 
also be deduced that they were all just salt formations. Crystals from strontium chloride were not 
yet suitable for diffraction; nonetheless, preliminary results were promising. Future studies will 
focus on refining the crystallization conditions for this additive. Rather than applying similar 
crystallization conditions as 1,8-diaminooctane, broad parameters will be set and adjusted 
accordingly; a similar approach could be applied to calcium chloride.  After all, there is little 
guarantee that any successful conditions from one additive would be applicable to another. 
Crystal structures of huDHFR, CaDHFR, and CgDHFR each bound to UCP111E would ideally 
be determined and compared separately to aid in the design of future anti-folate compounds. 
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Appendix A 
 
Figure 1 
Non-volatile additive: 1,8-diaminooctane 
 
I: 1% 
II: 3% 
III: 5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A4, II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B1, III 
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Figure 2 
Non-volatile additive: 1,8-diaminooctane 
 
I: 3% 
II: 5% 
III: 7% 
 
 
 
 
 
 
 
 
 
 
B4, III 
 
 
 
 
 
 
 
 
 
 
 
 
 
C5, III 
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Figure 3 
Non-volatile additive: 1,8-diaminooctane 
 
I: 5% 
II: 7% 
III: 10% 
 
 
 
 
 
 
 
 
 
 
 
A4, I B5, III 
 
C1, II 
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Figure 4 
Non-volatile additive: 1,8-diaminooctane 
 
I: 7% 
II: 10% 
III: 13% 
 
 
 
 
 
 
 
 
 
 
C1, III B3, I 
 
B5, II 
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Figure 5 
Non-volatile additive: 1,8-diaminooctane 
 
I: 10% 
II: 15% 
III: 20% 
 
 
 
 
 
 
 
 
 
B2, II C4, III 
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Figure 6 
Non-volatile additive: 1,8-diaminooctane 
 
I: 10% 
II: 15% 
III: 20% 
 
 
 
 
 
 
 
 
 
B5, II C3, III  
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Figure 7 
Non-volatile additive: Strontium Chloride 
  
I: 0.075 M 
II: 0.1 M 
III: 0.125 M 
 
 
 
 
 
 
A3, III B4, I C4, II 
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Figure 8 
Non-volatile additive: Calcium Chloride 
 
I: 0.1 M 
II: 0.1 M 
III: 0.15 M 
 
 
 
 
 
A4, II 
 
B5, II 
 
C1, III 
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Figure 9 
Non-volatile additive: Strontium Chloride 
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